247 related articles for article (PubMed ID: 22211286)
1. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
3. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
4. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
6. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
[TBL] [Abstract][Full Text] [Related]
7. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
9. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.
Jeng YM; Chang CC; Hu FC; Chou HY; Kao HL; Wang TH; Hsu HC
Hepatology; 2008 Oct; 48(4):1118-27. PubMed ID: 18802962
[TBL] [Abstract][Full Text] [Related]
10. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma.
Wachter DL; Schlabrakowski A; Hoegel J; Kristiansen G; Hartmann A; Riener MO
Am J Surg Pathol; 2011 Jun; 35(6):873-7. PubMed ID: 21566520
[TBL] [Abstract][Full Text] [Related]
12. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
15. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
17. Utilization of spectrins βI and βIII in diagnosis of hepatocellular carcinoma.
Hu S; Jue D; Albanese J; Wang Y; Liu Q
Ann Diagn Pathol; 2019 Apr; 39():86-91. PubMed ID: 30798076
[TBL] [Abstract][Full Text] [Related]
18. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma.
Ahmad I; Iyer A; Marginean CE; Yeh MM; Ferrell L; Qin L; Bifulco CB; Jain D
Hum Pathol; 2009 May; 40(5):726-34. PubMed ID: 19157505
[TBL] [Abstract][Full Text] [Related]
20. Utility of CD34 reactivity in evaluating focal nodular hepatocellular lesions sampled by fine needle aspiration biopsy.
Kong CS; Appenzeller M; Ferrell LD
Acta Cytol; 2000; 44(2):218-22. PubMed ID: 10740609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]